Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aceragen Inc ACGN

Healthcare Biotechnology
Aceragen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and... see more

Recent & Breaking News (NDAQ:ACGN)

Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncol

GlobeNewswire February 24, 2017

Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development

GlobeNewswire February 6, 2017

Research Reports Coverage on Biotech Stocks -- Idera Pharma, Ocular Therapeutix, Radius Health, and Grifols

PR Newswire January 27, 2017

Idera to Present at the 35th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2017

Research Reports Coverage on Biotech Stocks -- Idera Pharma, bluebird bio, Corcept Therapeutics, and PhaseRx

PR Newswire December 16, 2016

16 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  November 28, 2016

Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IMO-9200

GlobeNewswire November 28, 2016

Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125 from Ongoing Phase 1 Dose Escalation in Clinical Trial in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Trea

GlobeNewswire November 11, 2016

Idera to Present at the Stifel 2016 Healthcare Conference

GlobeNewswire November 10, 2016

Idera Pharmaceuticals to Provide Multiple Presentations on Intratumoral IMO-2125 at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 9, 2016

How These Biotech Stocks are Faring? -- Ocular Therapeutix, Idera Pharma, Conatus Pharma, and Infinity Pharma

PR Newswire November 4, 2016

Idera Pharmaceuticals Reports Third Quarter 2016 Financial Results

GlobeNewswire October 28, 2016

18 Biggest Mid-Day Losers For Friday

Benzinga.com  October 7, 2016

Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

GlobeNewswire October 7, 2016

Mid-Afternoon Market Update: Crude Oil Up 1.5%; Alnylam Pharma Shares Tumble On Revusiran Termination

Benzinga.com  October 6, 2016

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  October 6, 2016

Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire October 5, 2016

Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society

GlobeNewswire September 27, 2016

Idera Pharmaceuticals Reports Promising Data from Ongoing Phase 1 Dose Escalation in Clinical Trial of Intra-tumoral IMO-2125 in Combination with Ipilimumab in Patients with PD-1 Refractory Metastatic Melanoma

GlobeNewswire September 26, 2016

Mid-Day Market Update: Tobira Therapeutics Jumps Following Allergan Buyout; HNI Shares Slide

Benzinga.com  September 20, 2016